Vermillion Announces Additions to Commercial Management Team

AUSTIN, Texas, Aug. 14, 2014 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a multivariate diagnostics company focused on gynecologic cancers and women's health, has appointed David Jansen as Vice President of Marketing. In addition, the company has created the new position of Vice President of Sales and Managed Markets, which will be filled and announced shortly.

David Jansen has been hired to the new position of Vice President of Marketing. David joins us from Myriad Genetics, where he has held senior marketing roles for the last seven years. David has an undergraduate degree from Northern Arizona University and an MBA from the University of Phoenix.

"A major goal of Vermillion in 2014 is to take full control of our commercial progression as we re-define our strategic relationship with Quest," said James LaFrance, Vermillion's Chairman, President and Chief Executive Officer. "We have expanded our direct sales force, opened our new commercial CLIA lab, ASPiRA LABS, and are now supplementing our management team with critical commercial expertise and experience. David Jansen's expert knowledge of the women's health market with an industry leader, and his twenty years of global commercial marketing strategy expertise will be a tremendous asset for Vermillion. We will also soon be in a position to announce our new Vice President of Sales and Managed Markets who will be responsible for leading our direct selling efforts to health care professionals and all reimbursement efforts with commercial payers."

Both positions will report directly to the Chief Executive Officer. As part of this re-organization and re-structure, Marian Sacco, the Company's Chief Commercial Officer, will be leaving the Company.  Ms. Sacco joined Vermillion in December of 2013.

About Vermillion
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic oncology and women's health.

The company's lead diagnostic, OVA1^®, is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using an innovative algorithmic approach. As the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, OVA1 represents a new class of software-based diagnostics. For additional information, including published clinical trials, visit www.vermillion.com.

About ASPiRA LABS
ASPiRA LABS is an innovative diagnostic services laboratory founded by Vermillion, Inc., a leader in women's health diagnostics. The laboratory's goal is to provide high quality, innovative testing for women to help address unmet women's health needs. ASPiRA LABS' specialized services are grounded in evidence-based medicine, while providing access to novel biomarker diagnostic tools designed to help health care professionals offer the most precise diagnoses and treatment guidance for their patients. To learn more about ASPiRA LABS, visit www.aspiralab.com.

Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the roles of the Vice President of Sales and Managed Markets and Vice President of Marketing. These forward-looking statements are based on Vermillion's expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements, including the factors that are described in Vermillion's Form 10-K for the year ended December 31, 2013 and Vermillion's Form 10-Q for the quarter ended March 31, 2014 filed with the Securities and Exchange Commission.  Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

Investor Relations Contact:
Eric Schoen
Vice President, Finance and Chief Accounting Officer
Tel 512-519-0424
[email protected]

SOURCE Vermillion, Inc.